Novacyt S.A. ("Novacyt", the "Company" or the "Group"): Non-Executive Director Change
07 Diciembre 2022 - 1:00AM
Business Wire
Regulatory News:
Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international
specialist in clinical diagnostics, announces that Edwin Snape has
informed the Board that he wishes to retire after 14 years with the
expanded Group, both as a Non-Executive Director (NED) of Novacyt
and formerly NED of Lab21, which was acquired by the Group in 2014.
Ed’s retirement from the Board will take effect from 31 December
2022.
James Wakefield, Chairman of Novacyt, added:
“On behalf of the Board, I would like to thank Ed for the
considerable contribution, input and support that he has provided
to the Group during his 14 year tenure and wish him well with his
retirement.”
Ed Snape, NED of Novacyt, commented:
“It has been a pleasure to have worked with so many exceptional
people at Novacyt and Lab21 over the years and I would like to
thank them all for their hard work and support. I look forward to
watching Novacyt continue on its exciting journey to become a
leading, global clinical diagnostics company in infectious
diseases.”
– End –
About Novacyt Group
The Novacyt Group is an international diagnostics business
generating an increasing portfolio of in vitro and molecular
diagnostic tests. Its core strengths lie in diagnostics product
development, commercialisation, contract design and manufacturing.
The Company supplies an extensive range of high-quality assays and
reagents worldwide. The Group directly serves microbiology,
haematology and serology markets as do its global partners, which
include major corporates.
For more information, please refer to the website:
www.novacyt.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221206006167/en/
Novacyt SA James Wakefield, Non-Executive Chairman James
McCarthy, Acting Chief Executive Officer +44 (0)1276 600081 SP
Angel Corporate Finance LLP (Nominated Adviser and Broker)
Matthew Johnson / Charlie Bouverat (Corporate Finance) Vadim
Alexandre / Rob Rees (Corporate Broking) +44 (0)20 3470 0470
Numis (Joint Broker) James Black / Freddie Barnfield /
Duncan Monteith +44 (0)20 7260 1000 Allegra Finance (French
Listing Sponsor) Rémi Durgetto / Yannick Petit +33 (1) 42 22 10
10 r.durgetto@allegrafinance.com; y.petit@allegrafinance.com FTI
Consulting (International) Victoria Foster Mitchell / Alex Shaw
+44 (0)20 3727 1000 victoria.fostermitchell@fticonsulting.com /
Alex.Shaw@fticonsulting.com FTI Consulting (France) Arnaud
de Cheffontaines +33 (0)147 03 69 48
arnaud.decheffontaines@fticonsulting.com
Novacyt (EU:ALNOV)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024
Novacyt (EU:ALNOV)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024
Real-Time news about Novacyt (Euronext): 0 recent articles
Más de Novacyt Artículos de Noticias